SCHEMBL7218133

SCHEMBL7218133

CCCOCc1ccc(C(=O)OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.56
MAPT P10636 5/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA12 O43570 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
ALDH1A1 P00352 2/20 0.53
TSHR P16473 2/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9262378 0.90 NPC1 (0.56) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL10865547 0.87 MGLL (0.51) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL14660779 0.87 MGLL (0.51) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6665979 0.87 LOXL2 (0.66) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1627925 0.86 CYP4A11 (0.60) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2412752 0.86 LOXL2 (0.59) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL20963807 0.83 CYP4A11 (0.66) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL18105886 0.83 CYP4A11 (0.57) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL18105885 0.83 CYP4A11 (0.57) LOXL2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL5606050 0.83 TSHR (0.51) LOXL2MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed